Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1426235rdf:typepubmed:Citationlld:pubmed
pubmed-article:1426235lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1426235lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:1426235lifeskim:mentionsumls-concept:C0032043lld:lifeskim
pubmed-article:1426235lifeskim:mentionsumls-concept:C0023884lld:lifeskim
pubmed-article:1426235lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:1426235lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:1426235lifeskim:mentionsumls-concept:C0560013lld:lifeskim
pubmed-article:1426235lifeskim:mentionsumls-concept:C2700400lld:lifeskim
pubmed-article:1426235pubmed:issue1lld:pubmed
pubmed-article:1426235pubmed:dateCreated1992-12-2lld:pubmed
pubmed-article:1426235pubmed:abstractTextA high pH anion exchange chromatographic (HPAEC) system for the separation of isomeric sialo-oligosaccharide products was developed. Employing this system, using Gal beta 1-->4GlcNAc beta 1-->2Man alpha 1-->6Man beta 1-->4GlcNAc as a substrate, a Gal beta 1-->4GlcNAc-R alpha 2-->3-sialyltransferase activity was detected for the first time in human liver. This activity is expressed together with the prevalent alpha 2-->6-sialyltransferase. Furthermore, in addition to the major alpha 2-->3-sialyltransferase, a low but distinct activity of alpha 2-->6-sialyltransferase was detected in human placenta. This activity could not be found by methods based on methylation analysis or high resolution NMR spectroscopy. It is concluded that HPAEC, in combination with the use of the pentasaccharide as an acceptor substrate, is suited for the specific detection of minor, Gal beta 1-->4GlcNAc-specific sialyltransferase activities.lld:pubmed
pubmed-article:1426235pubmed:languageenglld:pubmed
pubmed-article:1426235pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1426235pubmed:citationSubsetIMlld:pubmed
pubmed-article:1426235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1426235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1426235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1426235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1426235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1426235pubmed:statusMEDLINElld:pubmed
pubmed-article:1426235pubmed:monthNovlld:pubmed
pubmed-article:1426235pubmed:issn0014-5793lld:pubmed
pubmed-article:1426235pubmed:authorpubmed-author:Van den...lld:pubmed
pubmed-article:1426235pubmed:authorpubmed-author:SchiphorstW...lld:pubmed
pubmed-article:1426235pubmed:authorpubmed-author:NemanskyMMlld:pubmed
pubmed-article:1426235pubmed:authorpubmed-author:KoelemanC ACAlld:pubmed
pubmed-article:1426235pubmed:issnTypePrintlld:pubmed
pubmed-article:1426235pubmed:day2lld:pubmed
pubmed-article:1426235pubmed:volume312lld:pubmed
pubmed-article:1426235pubmed:ownerNLMlld:pubmed
pubmed-article:1426235pubmed:authorsCompleteYlld:pubmed
pubmed-article:1426235pubmed:pagination31-6lld:pubmed
pubmed-article:1426235pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:meshHeadingpubmed-meshheading:1426235-...lld:pubmed
pubmed-article:1426235pubmed:year1992lld:pubmed
pubmed-article:1426235pubmed:articleTitleHuman liver and human placenta both contain CMP-NeuAc:Gal beta 1-->4GlcNAc-R alpha 2-->3- as well as alpha 2-->6-sialyltransferase activity.lld:pubmed
pubmed-article:1426235pubmed:affiliationDepartment of Medical Chemistry, Vrije Universiteit, Amsterdam, The Netherlands.lld:pubmed
pubmed-article:1426235pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1426235pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1426235pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed